The EGFR signaling plays a role in signaling the downstream BRAF. Therefore, we conduct testing on KRAS and EGFR mutation in thyroid cancer patients who did not harbor BRAF mutation. This evidence concerns the gene BRAF and thyroid gland carcinoma.